Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Detection reagent of biomarker for early diagnosis of pancreatic cancer

A technology of biomarkers and detection reagents, applied in the field of early disease detection, can solve problems such as small sample size, lack of verification tests, and inability to detect miRNA, and achieve improved specificity and sensitivity, high sensitivity and high positive predictive value. Effect

Pending Publication Date: 2020-10-09
上海思路迪医学检验所有限公司
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the sample size of these studies is small, the number of miRNAs detected in extracellular vesicles is small, there is no chronic pancreatitis sample as a control, or the lack of independent validation experiments, microarray-based or RT-PCR techniques cannot detect unknown miRNAs in extracellular vesicles. miRNAs, leading to a lack of miRNAs derived from blood extracellular vesicles as effective biomarkers to differentiate chronic pancreatitis from pancreatic cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Detection reagent of biomarker for early diagnosis of pancreatic cancer
  • Detection reagent of biomarker for early diagnosis of pancreatic cancer
  • Detection reagent of biomarker for early diagnosis of pancreatic cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0030] In order to understand the content of the present invention more clearly, it will be described in detail with reference to the drawings and embodiments.

[0031] All miRNAs involved in the present invention are mature miRNAs annotated in the miRBase database (http: / / www.mirbase.org / ).

[0032] The blood extracellular vesicle miRNA biomarker of the present invention is further combined with the expression level of carbohydrate antigen CA19-9 in the serum to establish a identification model to help improve the accuracy of early diagnosis of pancreatic cancer, prevent over-medication, and reduce additional costs for patients. Suffering and waste of clinical medical resources.

[0033] The screening process of the blood extracellular vesicle miRNA biomarkers hsa-miR-95-3p and hsa-miR-26b-5p specifically detected by the detection reagent of the present invention comprises the following steps:

[0034] (1) Study cohort and clinical information

[0035] In this study, a tota...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a detection reagent of a biomarker for early diagnosis of pancreatic cancer. The biomarker comprises a blood extracellular vesicle miRNA biomarker hsa-miR-95-3p and a blood extracellular vesicle miRNA biomarker hsa-miR-26b-5p, and the blood extracellular vesicle miRNA biomarkers can be further combined with carbohydrate antigens CA19-9 in serum to serve as the biomarker for distinguishing pancreatic cancer and pancreatitis. The blood extracellular vesicle miRNA is proposed and verified for the first time as the biomarker, has high specificity, high sensitivity and highpositive prediction value when being combined with the expression level of the carbohydrate antigen CA19-9 in serum to distinguish pancreatitis and pancreatic cancer patients, and has important significance for early diagnosis of pancreatic cancer.

Description

technical field [0001] The invention relates to the technical field of early detection of diseases, in particular to a detection reagent for biomarkers used for early diagnosis of pancreatic cancer. Background technique [0002] Pancreatic cancer is a malignant tumor with high morbidity and mortality worldwide, and more than 90% of them are pancreatic ductal adenocarcinoma. Due to the special anatomical location of the pancreas, the onset is asymptomatic in the early stage, and it often occurs after the tumor invades the surrounding tissue. At this time, the patient has lost the opportunity for surgical resection and is easily confused with chronic pancreatitis. The prognosis of pancreatic ductal adenocarcinoma is poor, and the five-year survival rate of patients is less than 8%. On the other hand, sometimes pancreatic masses are indistinguishable from chronic pancreatitis or benign pancreatic cysts, resulting in ambiguous pathological evaluation of lesion biopsies, and chr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886C12Q1/6883G16B5/00G06K9/62
CPCC12Q1/6886C12Q1/6883G16B5/00C12Q2600/178C12Q2600/158G06F18/24
Inventor 俞文隆王向张大东许晓雅刘士毅杨旻张亚楠陈灏郭世伟金钢
Owner 上海思路迪医学检验所有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com